AZN News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AZ

Mkt Cap

$257.57B

Volume

2.76M

Next Earnings

November 5th

Chart Earnings News About Dividends Insider Filings

AZN vs. MRK: Comparing Keytruda, Pipelines and Growth StrategiesAstraZeneca and Merck are compared as investment opportunities in the pharmaceutical sector. AstraZeneca targets $80 billion in revenues by 2030 with 20 planned new medicine launches but faces patent expirations, pricing pressures in China, and recent pipeline setbacks. Merck relies heavily on blockbuster drug Keytruda (peak sales $35 billion by 2028) but faces patent expiration in 2028 and biosimilar competition. Merck receives a Zacks Rank #3 (Hold) while AstraZeneca receives Zacks Rank #5 (Strong Sell), making Merck the preferred choice despite higher valuation multiples.Zacks Investment Research · Sep 21, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish OutlookIonis Pharmaceuticals stock has plummeted over 40% this year due to late-stage clinical trial failures and ongoing losses, yet Wall Street analysts maintain a bullish outlook with an average price target of $83.82. Despite setbacks with pelacarsen and eplontersen programs, the company's strong ASO technology platform, solid $2.1 billion cash position, and recent FDA approval of Zanvastro for Alexander disease provide potential for long-term investors willing to wait several years for profitability.The Motley Fool · Sep 20, 2026

Wall Street's Bull Case for Bristol Myers Squibb Is Getting LouderBristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.The Motley Fool · Sep 20, 2026

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.Zacks Investment Research · Sep 18, 2026

Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?While Wall Street analysts maintain a bullish average brokerage recommendation (ABR) of 1.56 for Astrazeneca with 17 Strong Buy ratings, the Zacks Rank system assigns the stock a Strong Sell rating (#5). This contradiction stems from a 10.3% decline in consensus earnings estimates over the past month to $9.16, indicating analyst pessimism about the company's earnings prospects. The article cautions investors against relying solely on brokerage recommendations, which often exhibit positive bias, and suggests the Zacks Rank's focus on earnings estimate revisions is a more reliable predictor of near-term stock performance.Zacks Investment Research · Sep 16, 2026

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta TherapeuticsThe global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.GlobeNewswire Inc. · Sep 15, 2026

New Strong Sell Stocks for September 15thZacks has added three stocks to its Strong Sell list today: Aptiv PLC, a vehicle components manufacturer with a 4.9% downward earnings revision; AstraZeneca PLC, a biopharmaceutical company with a 9.1% downward earnings revision; and Bank OZK, a banking services provider with a 3.2% downward earnings revision over the last 60 days.Zacks Investment Research · Sep 15, 2026

Why the Market Dipped But Astrazeneca (AZN) Gained TodayAstrazeneca (AZN) rose 2.25% to $163.78 in the latest session, outperforming the broader market decline. However, the company faces headwinds with consensus EPS estimates down 8.49% over the last 30 days and a Zacks Rank of #4 (Sell). While revenue is expected to grow 5.82% year-over-year, the stock trades at a forward P/E of 17.14, below its industry average, and the Medical-Biomedical and Genetics industry ranks in the bottom 34% of all sectors.Zacks Investment Research · Sep 14, 2026

Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsightThe lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.GlobeNewswire Inc. · Sep 14, 2026

AZN's Etcamah Fails Late-Stage Study for First-line Breast CancerAstraZeneca announced that its phase III SERENA-4 study evaluating Etcamah combined with Pfizer's Ibrance failed to meet its primary endpoint of progression-free survival as first-line treatment for ER-positive, HER2-negative advanced breast cancer, though numerical improvement was observed. The failure does not affect Etcamah's recent FDA approval for a switch strategy in patients with ESR1 resistance mutations.Zacks Investment Research · Sep 14, 2026

AZ

AZNAstraZeneca PLC

AZN

Pay with—

Available Balance0.00

Your PositionYou don't own any AZN yet.

Related Tickers

Earnings

Dividends

Last · Aug 7Semi-annual

Amount$1.06

Yield3.20%

Annual$5.38